GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (MEX:ALT1) » Definitions » Net Policyholder Benefits/Claims

Altimmune (MEX:ALT1) Net Policyholder Benefits/Claims


View and export this data going back to 2021. Start your Free Trial

What is Altimmune Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Altimmune Business Description

Industry
Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.